Horizon Pharma traded at $116.30 this Thursday October 5th, increasing $0.05 or 0.04 percent since the previous trading session. Looking back, over the last four weeks, Horizon Pharma gained 0.69 percent. Over the last 12 months, its price rose by 71.31 percent. Looking ahead, we forecast Horizon Pharma to be priced at 112.81 by the end of this quarter and at 102.96 in one year, according to Trading Economics global macro models projections and analysts expectations.
Horizon Therapeutics plc is a biotechnology company that is focused on researching, developing and commercializing medicines that address critical needs for people impacted by rare, autoimmune and serious inflammatory diseases. The Company's portfolio is composed of approximately 12 medicines in the areas of rare diseases, gout, ophthalmology and inflammation. The Company has two reportable segments: the orphan and the inflammation segment. The orphan segment includes the medicines TEPEZZA, KRYSTEXXA, RAVICTI, PROCYSBI, ACTIMMUNE, BUPHENYL, QUINSAIR, UPLIZNA and also the Company’s research and development (R&D) programs. TEPEZZA is a monoclonal antibody and a targeted inhibitor of the insulin-like growth factor-1 receptor (IGF-1R). KRYSTEXXA is an infused medicine for uncontrolled gout. The Company's other orphan segment medicines, RAVICTI, PROCYSBI and ACTIMMUNE, treats serious chronic diseases. The inflammation segment includes PENNSAID 2%, DUEXIS, RAYOS and VIMOVO medicines.